IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus

Area of Science:

• Endocrinology
• Immunology
• Cardiology

Background:

• Type 2 diabetes mellitus (T2DM) is a global epidemic characterized by insulin resistance and beta-cell loss.
• T2DM is linked to chronic inflammation, with Interleukin-1 beta (IL-1β) exacerbating complications like cardiovascular disease.
• Current diabetes treatments primarily focus on hyperglycemia, often neglecting inflammation and associated risks.

Purpose of the Study:

• To review experimental and clinical data on IL-1β inhibitors for T2DM cardiovascular complications.
• To discuss the potential of IL-1β inhibitors as novel therapeutic agents for T2DM patients.

Main Methods:

• Review of existing literature on IL-1β inhibitors in T2DM.
• Analysis of pharmacological approaches targeting IL-1β pathways.
• Examination of clinical trial data and experimental findings.

Main Results:

• IL-1β plays a significant role in T2DM-related inflammation and cardiovascular complications.
• Pharmacological IL-1β inhibitors demonstrate potential in mitigating these adverse effects.
• Available IL-1β inhibitors include anakinra, rilonacept, canakinumab, and gevokizumab.

Conclusions:

• IL-1β inhibition represents a promising therapeutic strategy for T2DM.
• Targeting IL-1β may offer a dual benefit of glycemic control and cardiovascular protection.
• Further research is warranted to establish the full clinical utility of IL-1β inhibitors in T2DM management.